Efficacy and Safety of Long-Term Anticoagulation Therapy with Direct Oral Anticoagulants versus Vitamin K Antagonist in Patients with Cerebral Venous Thrombosis

Open Journal of Medical Sciences | Vol 3, Issue 1

Table 2. Characteristics of reviewed studies

Study (Year)	Anticoagulant	Time to initiation of AC (days)	Duration of AC	Recanalization	No Recanalization	Any Bleeding	New Intracranial Hemorrhage	Functional Outcome	Mortality
Ferro et al (2019)	Warfarin Dabigatran	5-15	5.15	35 (67%) 33 (60%)	17 (33%) 22 (40%)	12 (20%) 12 (20%)	2(3.8%) 0 (0%)	mRS 0-2: 56 (96.6%)mRS 3-5: 2 (2.3%) mRS 0-2 :58 (98.3%)mRS 3-5: 1 (1.7%)	0 (0%) 0 (0%)
Connor et al (2020)	Heparin/VKA Rivaroxaban	5-9	3	30 (73%) 57 (78%)	11 (27%) 16 (22%)	1 (2.4%) 5 (6.8%)	1 (2.4%) 0 (0%)	Recurrent CVT/Hemorrhage: 2 (4.9%) Recurrent CVT/Hemorrhage: 0 (0%)	0 (0%) 0 (0%)
Khorvash et al (2021)	Warfarin Rivaroxaban	2	3	NR	NR	0 (0%) 1 (4%)	On Admission: 7 (28%) Month 3: 0 (0%) Month 6:0 (0%) On Admission::2 (8%) Month 3:1 (4%) Month 6:(0%)	mRS On Admission: 3 (2.0, 4.0)¹ Month 3: 1 (0, 2.0)¹ Month 6: 0 (0, 2.0)¹ mRS On Admission:: 3 (1.5, 4.0)¹ Month 3: 1 (0, 1.0)¹ Month 6: 0 (0, 1.0)¹	0 (0%) 0 (0%)
Masqood et al (2021)	Warfarin Rivaroxaban	5	3-12	Month 3 17 (71%) Month 6 20 (83%) Bulan ke-12 24 (100%) Month 3 15 (71%) Month 6 18 (86%) Month 12 21 (100%)	Month 3 7 (29%) Month 6 4 (17%) Month 12 0 (0%) Month 3 6 (29%) Month 6 3 (14%) Month 12 0 (0%)	6 (25%) 2 (10%)	2 (8%) 0 (0%)	NIHSS² Month 3 NIHSS 0: 21 (88%) NIHSS 1-4: 3 (12%) Month 6 NIHSS 0: 23 (96%) NIHSS 1-4: 1 (4%) Month 3 NIHSS 0: 20 (95%) NIHSS 1-4: 1 (5%) Month 6 NIHSS 0: 20 (95%) NIHSS 1-4: 1 (5%)	0 (0%) 0 (0%)

¹ Data is shown as Median (first quartile, third quartile)

² Data is reported as NIHSS (National Institutes of Health Stroke Scale)

Abbreviations: AC, Anticoagulation; CVT: Cerebral Venous Thrombosis; LMWH: Low Molecular Weight Hepa-rin; UFH, Unfractionated Heparin; mRS, Modified Rankin Scale; NR: Not Reported; VKA, Vitamin K Antagonist